Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Phase 1

Withdrawn

Conditions: Diffuse Large B-Cell Lymphoma
Mediastinal B-cell Lymphoma

Interventions: Drug: Idelalisib
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2017-11-21

Last Posted Date: 2018-12-11

Lead Sponsor: Gilead Sciences

Registration Number: NCT03349346

Locations: 🇮🇹
Infantile Regina Margherita Hospital, Torino, Italy
🇮🇹
Istituto Giannina Gaslini, Genova, Italy
🇫🇷
Centre Hospitalier Régional Universitaire de Lille, Lille, France

and more 4 locations

Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma

Phase 1

Completed

Conditions: Lymphoblastic Leukemia
Lymphoblastic Lymphoma

Interventions: Drug: Everolimus
Drug: Nelarabine
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2017-11-01

Last Posted Date: 2023-07-21

Lead Sponsor: Emory University

Target Recruit Count: 8

Registration Number: NCT03328104

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States

and more 1 locations

Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 2

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Chidamide
Drug: prednisone
Drug: Cyclophosphamide
Drug: etoposide
Drug: Methotrexate

First Posted Date: 2017-10-26

Last Posted Date: 2017-10-26

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 102

Registration Number: NCT03321890

Locations: 🇨🇳
Department of Medical Oncology,Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer

Phase 2

Conditions: Ovarian Cancer

Interventions: Drug: Etoposide
Drug: Apatinib

First Posted Date: 2017-09-29

Last Posted Date: 2017-09-29

Lead Sponsor: Yang Zhijun

Target Recruit Count: 60

Registration Number: NCT03298074

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Phase 1

Recruiting

Conditions: AIDS-Related Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Biological: Filgrastim
Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Biological: Pegfilgrastim
Other: Pharmacological Study
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2017-07-18

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT03220022

Locations: 🇺🇸
University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

and more 18 locations

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Phase 3

Recruiting

Conditions: Mature B-cell Non-Hodgkin Lymphoma

Interventions: Drug: Rituximab window
Drug: Cyclophosphamide
Drug: Additional doses of Rituximab
Drug: Cytarabine
Drug: Dexamethasone
Drug: Etoposide
Drug: Doxorubicin hydrochloride
Drug: Ifosfamide
Drug: Vindesine Sulfate
Drug: Methotrexate
Drug: Prednisolone
Drug: Vincristine

First Posted Date: 2017-07-02

Last Posted Date: 2023-12-11

Lead Sponsor: University Hospital Muenster

Target Recruit Count: 650

Registration Number: NCT03206671

Locations: 🇫🇮
Turku University Hospital, Paediatric and Adolescent Haematology and Oncology, Turku, Finland
🇨🇭
Universitäts-Kinderspital, Pädiatrische Onkologie, Zürich, Switzerland
🇨🇭
Kinderspital Pädiatrische Hämatologie/ Onkologie, Luzern, Switzerland

and more 89 locations

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Azacitidine
Drug: Decitabine
Drug: Cytarabine
Drug: Daunorubicin
Drug: Etoposide
Combination Product: ITMHA
Drug: Idarubicin
Drug: Fludarabine
Drug: Mitoxantrone
Drug: Sorafenib
Drug: Erwinia asparaginase
Drug: G-CSF
Drug: Dexrazoxane
Drug: Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
Biological: Stem Cell Transplant

First Posted Date: 2017-05-23

Last Posted Date: 2024-05-29

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 206

Registration Number: NCT03164057

Locations: 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸
Children's Hospital of Central California, Madera, California, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 7 locations

Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

Phase 2

Completed

Conditions: Aggressive Non-Hodgkin Lymphoma

Interventions: Drug: Prednisone
Drug: Vinorelbine
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2017-05-19

Last Posted Date: 2021-12-20

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 21

Registration Number: NCT03161054

Locations: 🇮🇹
A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
🇮🇹
Ospedale di Castelfranco Veneto - Ematologia, Castelfranco Veneto, Italy
🇮🇹
Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS c/o CORE (II piano) - Ematologia, Reggio Emilia, Italy

and more 7 locations